Descriptive overview of Shingles, explaining its causes and available therapies.

Descriptive overview of Shingles, explaining its causes and available therapies.

 

Shingles Market” report has been added to DelveInsight

 

Shingles Overview

Shingles, also known as herpes zoster (HZ), is a viral infection caused by the chickenpox virus, varicella-zoster virus (VZV). Herpes zoster results from activation of the virus, which in many instances has remained latent for years following a primary chickenpox infection. Once active, the virus travels along a nerve to the skin and causes a rash.

 

Shingles Market:Forecast

DelveInsight’s “Shingles – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Shingles, historical and forecasted epidemiology as well as the Shingles market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Request free sample copy @ https://www.delveinsight.com/sample-request/shingles-market

 

Shingles Market: By Regions Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

 

Shingles Key Players

  • Novartis
  • GlaxoSmithKline
  • Maruho
  • And many others

 

Shingles Drugs

  • Famvir (famciclovir)
  • Valtrex (valacyclovir)
  • Amenalief (amenamevir)
  • And many others

 

Shingles Symptoms

Early symptoms of shingles may include fever and general weakness. During the 2 or 3 days before shingles development, most people have pain, a tingling sensation, or itching in a strip of skin (a dermatome) on one side of the body. Clusters of small, fluid-filled blisters surrounded by a small red area then develop on the strip of skin. Typically, the blisters occur only on the limited area of skin supplied by the infected nerve fibers. They are most common on the torso and face, but they can occur elsewhere as well. In rare cases, the rash appears on the lower body. Though, Shingles may develop at any age but is most common after age 50. The chance of developing shingles increases as people age.

 

Shingles Diagnosis

The signs and symptoms of herpes zoster are usually distinctive enough to make an accurate clinical diagnosis once the rash has appeared. If characteristic blisters appear in the typical pattern (on a strip of skin representing a dermatome), the diagnosis is clear. However, diagnosis of herpes zoster might not be possible in the absence of a rash (i.e., before rash or in cases of zoster without rash). Laboratory testing may be useful in cases with less typical clinical presentations, such as in people with suppressed immune systems who may have disseminated herpes zoster.

 

Shingles Market:Research

During chickenpox, the virus spreads in the bloodstream and infects collections of nerve cells (ganglia) of the spinal or cranial nerves. The virus remains in the ganglia in an inactive (dormant or latent) state. The virus may never cause symptoms again, or it may reactivate many years later. When it reactivates, the virus travels down the nerve fibers to the skin, where it creates painful sores resembling those of chickenpox. This outbreak of sores (shingles) almost always appears on a strip of the skin over the infected nerve fibers and only on one side of the body. This strip of skin, the area supplied by nerve fibers from a single spinal nerve region, is called a dermatome. Sores may also appear on the dermatomes or next to the affected dermatome.

 

Shingles Treatment

Shingrix vaccine has been approved by the US FDA to prevent shingles and is recommended for adults aged 50 years and older. Other than this vaccine, Shingles treatments include several antiviral drugs such as famciclovir or valacyclovir. These drugs do not cure the disease, but they can help relieve shingles symptoms and shorten their duration. Pain–reliving drugs, anti-inflammation drugs, narcotic medications and others are also prescribed for treatment of the symptoms.

 

Shingles Market: Report Highlights

  • Shingles symptoms are usually less severe in children than in adults.
  • Postherpetic neuralgia (PHN) is the most common complication of herpes zoster. PHN is pain that persists in the area where the rash once was for more than 90 days after rash onset, which can last for weeks or months, and occasionally, for years. About 1 in 10 adults with herpes zoster develop PHN.

 

Shingles Treatment Market

Treatment for Shingles must be initiated by a dermatologist or other health-care provider within 3 days of getting the rash. Ideally, if the treatment is initiated within 3 days, it can prevent possible complications, such as long-lasting nerve pain. However, receiving treatment after 3 days still has benefits.

 

Shingles Market Insights

Shingrix is a new shingles vaccine developed by GlaxoSmithKline and was approved by the US FDA in 2017. It contains inactivated varicella-zoster viral particles, which aids the body’s production of more antibodies that are necessary to fight the virus with a stronger immune system response. As an inactive vaccine, it may be administered to patients with compromised immune systems. It reduces the risk of getting shingles by more than 90% and it’s effective for five years.

 

Shingles Emerging Key Players

There are a few emerging key players, which are expected to enter the Shingles market in the coming years, which includes Nobelpharma (Fostoin), Curevo (CRV-101) and NanoViricides (NV-HHV-101). These therapies are under early phase clinical development and the launch of these therapies is expected during the forecast period of 2021–2030.

 

Table of content

1. Key Insights

2. Executive Summary of Shingles

3. Competitive Intelligence Analysis for Shingles

4. Shingles: Market Overview at a Glance

5. Shingles: Disease Background and Overview

6. Patient Journey

7. Shingles Epidemiology and Patient Population

9. Unmet Needs

10. Key Endpoints of Shingles Treatment

11. Marketed Products

12. Emerging Therapies

13. Shingles: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Shingles

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

Shingles Market Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Shingles Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

 

Why should you buy this report?

  • The report will help in developing business strategies by understanding trends shaping and driving the Shingles market
  • To understand the future market competition in the Shingles market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Shingles in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Shingles market
  • To understand the future market competition in the Shingles market

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

 

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/